[go: up one dir, main page]

MX2020008730A - Regímenes de dosificación de anticuerpo b7-h4. - Google Patents

Regímenes de dosificación de anticuerpo b7-h4.

Info

Publication number
MX2020008730A
MX2020008730A MX2020008730A MX2020008730A MX2020008730A MX 2020008730 A MX2020008730 A MX 2020008730A MX 2020008730 A MX2020008730 A MX 2020008730A MX 2020008730 A MX2020008730 A MX 2020008730A MX 2020008730 A MX2020008730 A MX 2020008730A
Authority
MX
Mexico
Prior art keywords
dosing regimens
antibody dosing
antibody
antigen
human
Prior art date
Application number
MX2020008730A
Other languages
English (en)
Inventor
Hong Xiang
Helen L Collins
Xiang Zhang
Sandeep P Inamdar
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MX2020008730A publication Critical patent/MX2020008730A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona métodos para administrar anticuerpos y fragmentos de unión al antígeno de estos que se unen específicamente a B7-H4 humano a un sujeto que lo necesita, por ejemplo, un paciente con cáncer.
MX2020008730A 2018-02-21 2019-02-21 Regímenes de dosificación de anticuerpo b7-h4. MX2020008730A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862633527P 2018-02-21 2018-02-21
US201962802100P 2019-02-06 2019-02-06
PCT/US2019/018963 WO2019165075A1 (en) 2018-02-21 2019-02-21 B7-h4 antibody dosing regimens

Publications (1)

Publication Number Publication Date
MX2020008730A true MX2020008730A (es) 2020-12-07

Family

ID=65686103

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008730A MX2020008730A (es) 2018-02-21 2019-02-21 Regímenes de dosificación de anticuerpo b7-h4.

Country Status (13)

Country Link
US (3) US20210070862A1 (es)
EP (1) EP3755719A1 (es)
JP (2) JP7258038B6 (es)
KR (1) KR20200123169A (es)
CN (1) CN111868089A (es)
AU (1) AU2019226009A1 (es)
BR (1) BR112020016990A2 (es)
CA (1) CA3091161A1 (es)
IL (1) IL276623A (es)
MA (1) MA51902A (es)
MX (1) MX2020008730A (es)
SG (1) SG11202007820QA (es)
WO (1) WO2019165075A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306144B2 (en) 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
MX2020008736A (es) * 2018-02-21 2020-12-07 Five Prime Therapeutics Inc Formulaciones de anticuerpos b7-h4.
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
EP3867274A1 (en) * 2018-10-15 2021-08-25 Five Prime Therapeutics, Inc. Combination therapy for cancer
AU2022205057A1 (en) 2021-01-04 2023-07-13 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
EP1522590B1 (en) 2000-06-28 2009-08-26 Glycofi, Inc. Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP2339004B1 (en) 2002-03-19 2015-02-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
ES2543734T3 (es) 2003-01-22 2015-08-21 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
CA2605781A1 (en) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Antigen binding molecules having modified fc regions and altered binding to fc receptors
KR20080094064A (ko) 2006-01-17 2008-10-22 바이오렉스 쎄라퓨틱스, 인코포레이티드 식물에서 ｎ-글리칸의 인간화 및 최적화 조성물 및 방법
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
EP2756094B1 (en) * 2011-08-15 2017-12-27 Medlmmune, LLC Anti-b7-h4 antibodies and their uses
SG11201504764SA (en) * 2012-12-19 2015-07-30 Amplimmune Inc Anti-human b7-h4 antibodies and their uses
DK3027651T3 (en) 2013-08-01 2019-04-15 Five Prime Therapeutics Inc AFUCOSYLED ANTI-FGFR2IIIB ANTIBODIES
CN107299085B (zh) * 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
US11306144B2 (en) * 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
MX2020008736A (es) * 2018-02-21 2020-12-07 Five Prime Therapeutics Inc Formulaciones de anticuerpos b7-h4.

Also Published As

Publication number Publication date
KR20200123169A (ko) 2020-10-28
BR112020016990A2 (pt) 2021-02-23
CA3091161A1 (en) 2019-08-29
IL276623A (en) 2020-09-30
EP3755719A1 (en) 2020-12-30
US20230287123A1 (en) 2023-09-14
US20240317864A1 (en) 2024-09-26
JP7258038B6 (ja) 2023-04-25
JP2023089063A (ja) 2023-06-27
AU2019226009A1 (en) 2020-09-03
US20210070862A1 (en) 2021-03-11
SG11202007820QA (en) 2020-09-29
WO2019165075A1 (en) 2019-08-29
MA51902A (fr) 2021-05-26
JP7258038B2 (ja) 2023-04-14
CN111868089A (zh) 2020-10-30
JP2021513997A (ja) 2021-06-03

Similar Documents

Publication Publication Date Title
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
PH12018501554A1 (en) Ror1 antibody compositions and related methods
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MX2021000392A (es) Anticuerpos anti-mesotelina.
ZA201803079B (en) Anti-dr5 antibodies and methods of use thereof
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
NZ760342A (en) Cd38 modulating antibody
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
ZA202008095B (en) Humanized antibodies against psma
NZ761838A (en) Cd38 antibody
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
MX2021004226A (es) Terapia combinada contra el cáncer.
NZ761020A (en) Cd38 modulating antibody
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof